The FDA rolled out an expedited Investigational New Drug (IND) pilot program designed to reduce bottlenecks in clinical trial applications. The IND pilot is part of HHS’s effort to onshore clinical trials and includes an initiative labeled “Operation TrialBlazer.” According to the program description, the pilot aims to apply more risk-proportionate, phase-appropriate judgment in early development and to move processes that are often sequential in parallel. A clinical trials executive from TruTechnologies said review standards and timelines remain the same, clarifying that the acceleration applies to submission preparation rather than scientific review. The move comes as companies weigh differing international timelines—Australia and China have been cited as having faster routes into the clinic—so the pilot signals an attempt to strengthen U.S. competitiveness in early clinical entry rather than to shorten review by fiat.